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Abstract
Background: Type 1 diabetes is an autoimmune disease caused by T cell-mediated destruction of the insulin-
producing β-cells in the pancreas. Therefore, approaches that effectively halt the pathogenic T cell response are
predicted to have preventive or therapeutic benefit for type 1 diabetes patients. We previously demonstrated that
long-term blocking of IL-7 signaling, which is critical for the survival and function of T cells, prevented and reversed
type 1 diabetes in non-obese diabetic mice. However, such persistent inhibition of T cell responses raises concerns
about causing immunodeficiency. Here, we asked whether a reduced duration of the treatment with anti-IL-7Rα
antibodies retained efficacy in preventing diabetes. Moreover, we sought to identify immunoregulatory mechanisms
induced by anti-IL-7Rα administration.
Results: Anti-IL-7Rα antibodies were administered to prediabetic NOD mice for 3 weeks and blood samples were
taken at the end of treatment and 2 weeks later to analyze changes in T cell phenotypes in response to IL-7Rα
blockade. We found that the co-inhibitory receptors LAG-3, Tim-3 and PD-1 were increased on peripheral blood CD4+
and CD8+ T cells from anti-IL-7Rα-treated mice. Expression of these receptors contributed to reduced T cell cytokine
production in response to TCR stimulation. In addition, the frequency of Tregs within the circulating CD4+ T cells was
increased at the end of anti-IL-7Rα antibody treatment and these Tregs showed a more activated phenotype. In vitro
restimulation assays revealed that effector T cells from anti-IL-7Rα-treated mice were more sensitive to co-inhibitory
receptor induction after TCR stimulation. Importantly, these changes were accompanied by delayed type 1 diabetes
disease kinetics.
Conclusions: Together, our data show that short-term blockade of IL-7Rα induces detectable changes in co-inhibitory
receptor expression and Treg frequencies in peripheral blood of NOD mice. These changes appear to have long-lasting
effects by delaying or preventing type 1 diabetes incidence. Hence, our study provides further support for using anti-IL-
7Rα antibodies to modulate autoreactive T cell responses.
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Background
Type 1 diabetes is a progressive autoimmune disease
caused by infiltration of autoreactive lymphocytes in
the islets of Langerhans which, ultimately, will destroy
the insulin-producing β-cells. As a result of the loss of
β-cells, blood sugar levels increase leading to a severe
risk of secondary organ complications. Despite current
advances in the understanding of type 1 diabetes,
treatment remains largely limited to insulin replace-
ment therapy and attempts to prevent or cure the
disease in humans have so far been unsuccessful [1, 2].
IL-7 is a cytokine with an important role in T cell
survival and function and is an emerging target for the
treatment of multiple autoimmune diseases [3]. We and
others previously demonstrated that blocking IL-7 re-
ceptor alpha (IL-7Rα) prevented and reversed diabetes
in non-obese diabetic (NOD) mice and hence has
potential to be translated as an immunotherapy for
human type 1 diabetes [4, 5]. Initial analyses of CD4+ T
cells in anti-IL-7Rα-treated mice revealed increased
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expression of the co-inhibitory receptor Programmed
Death-1 (PD-1) in effector/memory CD4+ T cells (TE/
M) and an increased frequency of polyclonal regula-
tory T cells (Tregs) in lymphoid organs [4]. These
observations suggested that anti-IL-7Rα antibodies
shift the balance in the immune system from active
autoreactivity to a more regulated state, impacting
disease progression.
Co-inhibitory receptors play critical roles in maintaining
self-tolerance to autoantigens and are also associated with
“T cell exhaustion”, caused by chronic antigenic stimula-
tion of virus- and tumor-specific TE/M cells [6–8]. Hence,
increasing co-inhibitory receptor expression and “exhaus-
tion” in autoreactive T cells are predicted to be desirable
outcomes for the treatment of autoimmune diseases such
as type 1 diabetes. Loss-of-function studies of the co-
inhibitory receptors PD-1 and LAG-3 have demonstrated
a critical role for these co-inhibitory receptors in sup-
pressing anti-islet T cell responses in NOD mice, reflected
by an accelerated kinetics of disease course [9–12].
Contributions of other co-inhibitory receptors, e.g., Tim-3
and B7x, in regulating type 1 diabetes are emerging as well
[13, 14]. The role of Tregs in maintaining islet tolerance is
also firmly established and defects in Tregs may underlie
susceptibility for type 1 diabetes [15, 16]. Various ap-
proaches to increase Treg activity for the treatment of type
1 diabetes are intensively being developed and, in some
cases, have entered clinical trials [17].
The initiation of clinical trials to use anti-IL-7Rα anti-
bodies for the treatment of type 1 diabetes and other auto-
immune diseases [18] underscores the necessity to better
understand the treatment modalities and mechanisms
underlying protection against type 1 diabetes provided by
anti-IL-7Rα administration. Therefore, we treated predia-
betic NOD mice with a short course of anti-IL-7Rα anti-
bodies and expanded our analysis of co-inhibitory receptor
expression and Tregs. We found that in addition to PD-1,
LAG-3 and Tim-3 were also induced on T cells in re-
sponse to IL-7Rα blockade. Importantly, changes in these
receptors could be found not only in lymphoid organs but
on peripheral blood T cells as well and may serve as a bio-
marker of treatment efficacy. Furthermore, we show that
IL-7Rα blockade increases the frequency and changes the
phenotype of polyclonal Tregs. Together, our data suggest
that anti-IL-7Rα antibodies promote two key mechanisms
of protection against autoimmunity: increased expression
of co-inhibitory receptors and increased Treg activity.
Moreover, short-term IL-7Rα blockade retained some
capacity to alter the kinetics of the disease.
Methods
Mice
Prediabetic female NOD mice (9–11 weeks) were pur-
chased from The Jackson Laboratory (US). All animal
experiments were approved by the Institutional Animal
Care and Use Committee of Boston University Medical
Campus.
Diabetes assessment
Diabetes incidence was followed weekly by urine analysis
(Diastix, Bayer, US) and measuring of blood glucose
levels with a Contour glucose meter (Bayer; US). The
percentage of diabetic mice (glucose levels >250 mg/dL)
over a 32-weeks time course was calculated by the
Survival Curves method using GraphPad Prism.
In vivo antibody treatment
Anti-IL-7Rα (rat IgG2a, clone A7R34) antibodies for in
vivo blocking experiments were produced by a hybridoma
cell line and purified with Protein G Sepharose 4 Fast
Flow (GE Healthcare, US) in our laboratory. Rat IgG
(Jackson ImmunoResearch Laboratories, US) was used as
a control. For anti-IL-7Rα and rat IgG antibodies, 0.5 mg
was administered in PBS intraperitoneally.
In vitro stimulation assays and ELISA
Cells were cultured in RPMI 1640 media (Invitrogen,
US) supplemented with 1 mM each of L-glutamine, non-
essential amino acids, sodium pyruvate, Hepes, penicil-
lin, streptomycin, 50 μM 2-Mercaptoethanol (Gibco by
Life Technologies, US), and 10% FCS (Omega Scientific,
US), and incubated at 37 °C in 5% CO2. In vitro assays
to measure cytokine production were performed by
stimulating 5×105 cells from spleen and pancreatic lymph
nodes (PLN) with soluble anti-CD3 (1 μg/ml) (clone 145-
2C11; eBioscience, US) and anti-CD28 (2 μg/ml) (clone
37.51; eBioscience, US) antibodies in round-bottom 96-
well plates (BD Falcon, US) in the absence or presence of
blocking antibodies (10 μg/ml) for PD-L1 (clone MIH5),
LAG-3 (clone C9B7W) and Tim-3 (clone RMT3-23) (Bio
X Cell, US). Supernatants from the cultures were har-
vested after 18 h and IFN-γ and IL-2 content determined
by ELISA (eBioscience, US), following the manufacturer’s
instructions. For assays to measure induction of co-
inhibitory receptor expression, PLN cells from mice
treated with anti-IL-7Rα or rat IgG antibodies were stimu-
lated in vitro with soluble anti-CD3- (0.1 or 10 μg/ml)
and anti-CD28 (1 μg/ml) antibodies. Cell cultures
were set up in flat-bottom 96-well plates (BD Falcon,
US) and harvested after 3 days for flow cytometric
analysis.
Antibodies and staining procedures
Blood samples (50–100 μl) were drawn from mouse tail
vein and an equal volume of EDTA (50 mM) (Sigma,
US) was added immediately to avoid coagulation. Prior
to staining, erythrocytes were lysed for spleen and blood
samples. To distinguish live from dead cells, cells were
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preincubated with a fixable viability dye (eBioscience,
US) according to manufacturer’s instructions. Fc recep-
tors were blocked with anti-CD16/CD32 antibodies for
5 min at 4 °C before any antibody staining procedures
were started. The following antibodies were used for de-
tection of murine activation and proliferation markers
and co-inhibitory receptors: anti-CD4; anti-CD8; anti-
PD-1; anti-Tim-3; anti-LAG-3; anti-CD44; anti-Foxp3
and anti-CD25 (eBioscience, Biolegend or BD Pharmin-
gen, US). Extracellular staining was performed by incu-
bating with antibodies for 15–30 min at 4 ° C. For Foxp3
intracellular staining cells were fixed and permeabilized
with a Foxp3 staining buffer set (eBioscience, US)
following manufacturer’s instructions.
Flow cytometry
Phenotypic analysis of cell populations was performed
by multiparameter flow cytometry. Fluorescence inten-
sities were measured on a LSRII flow cytometer and data
were analyzed with FlowJo software.
Statistics
Statistically significant differences between groups were
determined using the Mantel–Cox log-rank test (for
diabetes incidence) and one- or two-tailed paired or
unpaired t tests (for flow cytometry data) using Graph
Pad Prism. P values ≤ 0.05 were considered significant.
Horizontal lines in graphs indicate statistical significance
(* = p ≤ 0.05, ** = p ≤ 0.005, *** = p ≤ 0.0005, ns = p > 0.05).
Results
A short course of IL-7Rα blocking antibodies delays type
1 diabetes onset in NOD mice
We and others previously demonstrated that sustained,
long-term treatment (14 weeks) of NOD mice with anti-
IL-7Rα monoclonal antibodies (mAbs) robustly prevented
diabetes incidence [4, 5]. However, such long-term
treatment was accompanied by significant depletion of
lymphocyte populations over time, raising concerns about
broad immunosuppression and questioning the potential
of translating this preventive strategy to the clinic. There-
fore, we asked whether a treatment of limited duration
with anti-IL-7Rα mAbs would retain benefit for long-term
prevention of type 1 diabetes. Treatment was started at
11 weeks of age, when insulitis is known to be evident in
NOD mice [19], hence this cohort represented a model of
secondary prevention (Fig. 1a). Four doses (0.5 mg each)
of anti-IL-7Rα mAbs or control rat IgG were administered
intraperitoneally on days 0, 5, 15 and 19. Blood was drawn
2 and 16 days after the last dose was given to evaluate
anti-IL-7Rα-induced changes in blood T lymphocytes. In
the group that received rat IgG, mice started to become
hyperglycemic at 12 weeks of age, whereas the mice
treated with anti-IL-7Rα mAbs showed a significant delay
in diabetes onset (Fig. 1b). Overall incidence was reduced
from ~80% to ~60%, suggesting that in some cases
secondary prevention can be achieved with temporary IL-
7Rα blockade in prediabetic mice. Thus, a short treatment
with blocking antibodies for IL-7Rα retains efficacy to
A
B
Fig. 1 A short-term treatment with anti-IL-7Rα antibodies delays and prevents diabetes in NOD mice. a Experimental design outline: 11-week old
prediabetic female NOD mice received four doses of 0.5 mg anti-IL-7Rα (n = 10) or rat IgG (n = 10) antibodies on days 0, 5, 15 and 19. Blood was
drawn at day 21 and 35 and T cell populations were analyzed by flow cytometry, and, b diabetes incidence was followed in mice that received
anti-IL-7Rα antibodies (black circles) or rat IgG (white circles) measuring urine and blood glucose levels until 32 weeks of age. Data were pooled
from two independent experiments (n = 20). P value is indicated in the figure
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delay and, in some cases, prevent diabetes progression,
supporting continued efforts to translate anti-IL-7Rα anti-
bodies for the prevention and treatment of type 1
diabetes.
Circulating T lymphocytes from anti-IL-7Rα-treated NOD
mice show enhanced expression of multiple co-inhibitory
receptors
To gain insight in the changes that occur in T cell phe-
notypes after short-term IL-7Rα blockade, we performed
a flow-cytometric analysis of peripheral blood T cell sub-
sets from treated mice two (day 21) and sixteen (day 35)
days after the final antibody administration (Fig. 2). Our
previous studies showed that increased expression of the
co-inhibitory receptor PD-1 in CD4+ TE/M cells from
anti-IL-7Rα-treated NOD mice contributed to protec-
tion from type 1 diabetes [4]. However, anti-PD-L1 anti-
bodies did not efficiently restore diabetogenicity in CD4+
TE/M cells isolated from anti-IL-7Rα-treated NOD mice,
suggesting that additional protective mechanisms are in-
duced by IL-7Rα blockade [4]. Therefore, in addition to
PD-1, we analyzed the expression of the co-inhibitory
receptors LAG-3 and Tim-3, which are known to play
important roles in limiting autoimmunity [12, 20, 21], in
CD4+ and CD8+ T cells (Fig. 2). Confirming our previous
observations in lymphoid organs [4], the percentage of
PD-1+ CD44high cells within CD4+Foxp3− TE/M cells and
CD44highCD8+ TE/M cells was elevated 2 days after the
end of the treatment (day 21) with anti-IL-7Rα vs. rat
IgG antibodies (Fig. 3a). Interestingly, these differences
were not maintained 2 weeks after the end of treatment.
To the contrary, Tim-3 and LAG-3 expression in periph-
eral blood CD4+ and CD8+ TE/M cells was not increased
when measured immediately after treatment but was
significantly increased 2 weeks after terminating anti-IL-
7Rα mAb administration (Fig. 3b, c). Using a separate
set of experimental mice, we analyzed the expression of
Tim-3 and LAG-3 in the pancreatic lymph nodes (PLN),
since this is the site where autoreactive T cells initially
respond to β-cell antigens [22]. We found that the fre-
quency of Tim-3+ and LAG-3+ cells within the CD4+
and CD8+ TE/M population increased after anti-IL-7Rα
mAb treatment (Fig. 3d, e), thus showing that in the
PLN these co-inhibitory receptors behave similarly as
PD-1, whose expression in PLN was analyzed previously
[4]. Taken together, these data show that T lymphocytes
in anti-IL7Rα-treated NOD mice exhibit a phenotype
reminiscent of T cell exhaustion, characterized by
expression of multiple co-inhibitory receptors [23].
Importantly, this phenotype is not only present in the
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Fig. 2 Flow cytometric analysis of peripheral blood T lymphocytes from anti-IL-7Rα − and rat IgG-treated NOD mice. a Gating strategy for TE/M cell
and Foxp3+ Treg populations. b Representative dot plots show PD-1 and CD44 percentages within the CD4 + Foxp3- and CD8+ TE/M cell populations.
c, d Representative histogram overlays of Tim-3 and LAG-3 expression within the CD4+ Foxp3- and CD8+ TE/M cell populations
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PLN but can be detected in peripheral blood samples,
suggesting this could be developed as a biomarker for
anti-IL-7Rα treatment. It is intriguing that the kinetics
of detecting Tim-3- and LAG-3-expressing cells in blood
differs from PD-1, suggesting that the former cells might
be retained longer in the PLN or induction of these re-
ceptors is delayed.
Peripheral blood Tregs show increased frequency and an
activated phenotype after anti-IL-7Rα antibody treatment
Tregs play a critical role in the prevention of autoimmun-
ity and deficiencies in their frequency and function are
therefore thought to contribute to the development of
autoimmune diseases such as type 1 diabetes [15, 16]. In
support of this, a lower frequency of Tregs has been de-
tected in the blood of young diabetic patients [24], and it
has been described that Tregs from type 1 diabetes
patients and NOD mice show functional deficits, possibly
related to defects in the IL-2/IL-2Rα pathway [25, 26]. To
evaluate whether the frequency and phenotype of circulat-
ing Tregs was altered in NOD mice after a short treatment
with anti-IL-7Rα mAbs, we analyzed peripheral blood
Tregs 2 days (day 21) and 2 weeks (day 35) after final anti-
IL-7Rα mAb or rat IgG administration (Fig. 2). The
percentage of peripheral blood Foxp3+ Tregs was signifi-
cantly increased 2 days after the end of treatment with
anti-IL-7Rα mAbs (Fig. 4a). Importantly, we found that
Tregs in peripheral blood of anti-IL-7Rα-treated mice
showed increased expression of Foxp3 (Fig. 4b). Increased
Foxp3 expression on a per cell basis has been associated
with Treg activation and improved suppressive activity
[27]. PD-1 expression was also increased in activated
(CD44high) Tregs from anti-IL-7Rα-treated mice (Fig. 4c),
further supporting the notion that IL-7Rα blockade
leads to Treg activation [28]. By 2 weeks after the end
of the treatment, Treg frequencies, Foxp3 expression
and PD-1 had returned to the same levels as controls.
However, a significant increase in Tim-3 expression
level was observed at this time, hence showing similar
expression kinetics as in TE/M cells (Fig. 4d). LAG-3
also showed a trend towards higher expression on day
35 (data not shown). Of note, higher levels of Tim-3
and LAG-3 in Tregs have been associated with an in-
creased suppressive activity of this population [29–31].
Fig. 3 IL-7Rα blockade induces multiple co-inhibitory receptors in CD4+ and CD8+ TE/M cells. a, b, c Prediabetic female NOD mice received anti-IL-7Rα
(black circles; n = 10) or rat IgG (white circles; n = 10) antibodies as in Fig. 1a and blood was drawn and analyzed as in Figs. 1a and 2. Percentage of PD-1
+CD44high cells and MFI of extracellular Tim-3 and LAG-3 within the peripheral blood CD4+Foxp3− (left) and CD8+ (right) TE/M cell populations were
determined by flow cytometry. All data are representative for two independent experiments. Each symbol represents one individual mouse. * = p≤
0.05, ** = p≤ 0.005. d, e Frequency of Tim-3+ and LAG-3+ cells within the activated (CD44high) CD4+Foxp3− and CD8+ TE/M cell populations in the PLN
of mice treated twice per week for two consecutive weeks with anti-IL-7Rα (black circles) or rat IgG (white circles) antibodies. Data are pooled from two
or three independent experiments (n = 3–8). * = p≤ 0.05, ns = p > 0.05
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Thus, our data indicate that short-term, systemic block-
ade of IL-7/IL-7Rα signaling not only detectably alters
the balance of Tregs/TE/M in peripheral blood but
changes Tregs qualitatively by increasing Foxp3 expres-
sion and co-inhibitory receptors, suggesting a more
activated, suppressive state.
Co-inhibitory receptor expression on T cells from anti-IL-
7Rα-treated mice impairs cytokine production
To analyze whether co-inhibitory receptors functionally
affected T cells from anti-IL-7Rα-treated mice, spleen
and pancreatic lymph node cells were stimulated in vitro
with anti-CD3 and anti-CD28 antibodies in the presence
or absence of PD-L1-, Tim-3- and LAG-3-blocking anti-
bodies (Fig. 5), and IFN-γ and IL-2 production
measured. We found that anti-IL-7Rα-treated T cells
produced less IFN-γ than controls, consistent with a less
functional state of the T cell population. Interestingly,
we found that blocking individual co-inhibitory receptors
did not efficiently restore IFN-γ production, but blocking
PD-L1, Tim-3 and LAG-3 simultaneously significantly in-
creased IFN-γ secretion (Fig. 5). IL-2 production was not
reduced in anti-IL-7Rα-treated T cells compared to con-
trols but blocking PD-L1 did result in enhanced secretion.
These data demonstrate that expression of co-inhibitory
receptors on T cells from anti-IL-7Rα-treated mice im-
pacts their functionality.
Absence of IL-7 signaling sensitizes T cells to express co-
inhibitory receptors in response to TCR stimulation
Co-inhibitory receptor expression is induced after T cell
activation and maintained in situations of chronic anti-
gen stimulation [6–8]. To ask how co-inhibitory recep-
tor expression behaves in response to TCR stimulation
in the absence of IL-7/IL-7Rα signals in vivo, we stimu-
lated T cells from the PLN of anti-IL-7Rα or Rat IgG-
treated NOD mice in vitro with a low (0.1 μg/ml) or
high (10 μg/ml) dose of anti-CD3 mAbs in the presence of
anti-CD28 (1 μg/ml) and evaluated LAG-3 and Tim-3 ex-
pression. We found that increasing TCR triggering led to
higher LAG-3 expression levels in activated (CD44high)
CD4+Foxp3− TE/M cells and Foxp3
+ Tregs from anti-IL-
7Rα-treated mice vs rat IgG controls (Fig. 6a). CD8+ T
cells did not show increased LAG-3 expression (data not
shown). Conversely, Tim-3 expression was increased after
strong TCR stimulation of IL-7-deprived CD8+ T cells
(Fig. 6b) but remained unaffected in CD4+ T cells (data
not shown), albeit with significant variability between ani-
mals. These data demonstrate that T cells persisting in the
A B
C D
Fig. 4 Inhibition of IL-7/IL-7Rα signaling promotes Tregs in peripheral blood. NOD mice were treated and peripheral blood analyzed as in Figs. 1a and 2.
a Representative dot plots (left) and summary (right) of frequency of CD4+ Foxp3+ Tregs within the CD4+ T cell population. b Representative histogram
(left) and summary of MFI (right) of Foxp3 expression levels within CD4+ Foxp3+ Tregs. c, d Representative dot plots (left) and summary (right) of PD-1+
CD44high cells (percentage) and Tim-3 (MFI) within the CD4+ Foxp3+ Treg population. Each symbol represents one individual mouse. All data are
representative for two independent experiments. * = p≤ 0.05, ** = p≤ 0.005, *** = p≤ 0.0005
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absence of IL-7 signals become more sensitive towards
TCR-induced co-inhibitory receptor expression, further
underscoring the idea that IL-7 protects activated T cells
from various inhibitory signals, thus promoting the auto-
immune response.
Discussion
In this study we sought to further characterize the protect-
ive mechanisms induced by treatment with anti-IL-7Rα
antibodies during an ongoing autoreactive T cell response.
We found that, in addition to PD-1, two other co-
inhibitory receptors, Tim-3 and LAG-3, show increased
expression in T cells from anti-IL-7Rα-treated NOD mice.
Moreover, IL-7Rα blockade promoted an expansion of the
polyclonal Treg population in NOD mice and, interest-
ingly, increased their activation status, indicating en-
hanced suppressive potential. Our results indicate that a
broad program of immunoregulation underlies the slower
disease kinetics afforded by IL-7Rα blockade in type 1 dia-
betes and, that markers of anti-IL-7Rα antibody activity
can be detected in peripheral blood following a short
course of treatment.
PD-1, Tim-3 and LAG-3 are co-inhibitory receptors that
are critical for controlling autoimmunity: studies with
blocking antibodies as well as gene-deficient mice demon-
strated that these pathways, individually or synergistically,
play important roles in type 1 diabetes and other auto-
immune diseases [9, 11–13, 32]. Hence, developing
methods to promote activity of these pathways is a prom-
ising approach towards novel therapies for type 1 diabetes
and other autoimmune diseases. Our data indicate that
this desired effect is achieved as a consequence of IL-7Rα
blockade. Interestingly, such a broad increase of multiple
co-inhibitory receptors in CD4+ Foxp3− and CD8+ TE/M
cells resembles the phenotype described in previous stud-
ies for exhausted T cells responding to tumors or chronic
viral infections [7, 8, 23]. In these settings, continuous
antigen exposure results in inhibited, “exhausted” T cells
that have lost effector functions (e.g., IFN-γ production)
necessary to effectively combat tumors and chronic viral
infections [8, 23, 33]. Importantly, IL-7 restored function-
ality in CD8+ T cells during chronic viral infections and in
tumor models [34, 35]. These observations thus support
the idea that IL-7 is an environmental factor promoting T
cell responses during chronic antigen challenge. As a cor-
ollary, inappropriate IL-7 signaling during autoreactive T
cell activation may contribute to the development of a
pathogenic T cell response. In this respect, murine
models of autoimmune diseases treated with inhibitors
of IL-7/IL-7Rα signaling show preventive or therapeutic
efficacy [4, 5, 36–38]. In many of these models, it remains
to be investigated whether increased co-inhibitory recep-
tor expression plays a role as a protective mechanism.
Due to the multiple immunoregulatory pathways induced
in anti-IL-7Rα-treated NOD mice, it will be a challenging
endeavor to unequivocally demonstrate the contribution
of each to controlling autoimmunity. In this regard, one
interesting finding from our study is that cells express-
ing PD-1 vs Tim-3 and/or LAG-3 appear with different
kinetics in the blood after anti-IL-7Rα mAb administra-
tion. This may be due to a slower kinetics of initial in-
duction or because Tim-3 and LAG-3-expressing cells
Fig. 5 Co-inhibitory receptors reduce cytokine production in T cells from anti-IL-7Rα-treated mice. Female, prediabetic NOD mice (11 weeks old)
were treated with anti-IL-7Rα or rat IgG antibodies twice a week for 2 weeks. At the end of treatment, spleen and PLN were harvested and pooled
cells stimulated in vitro with anti-CD3 and anti-CD28 antibodies, in the absence (white circles) or presence of blocking antibodies against PD-L1,
LAG-3 and Tim-3 (black diamonds). Supernatants were harvested after 18 h and IFN-γ (top panels) and IL-2 (bottom panels) levels determined by
ELISA. Each symbol represents one individual mouse (n = 3). * = p≤ 0.05, ** = p≤ 0.005
Vazquez-Mateo et al. BMC Immunology  (2017) 18:18 Page 7 of 10
are preferentially retained in the lymphoid organs while
PD-1 expressing cells belong to a population that more
readily enters the circulation. Besides enhanced co-
inhibitory receptor expression on TE/M cells, PD-1,
Tim-3 and LAG-3 were also increased on Tregs. Tregs
expressing PD-1 [39], Tim-3 [31] and LAG-3 [30] are
found at sites of active immune responses, e.g., in tu-
mors and transplants, and are thought to possess
higher suppressive activity.
The molecular mechanisms underlying increase of co-
inhibitory receptors in the absence of IL-7 signaling remain
to be determined. However, it is reasonable to speculate
that a direct effect of IL-7 on T cells during priming is in-
volved. For example, recent data show that IL-7 provides
additional early signals (increased ERK, STAT5, Akt) dur-
ing TCR engagement that promote optimal T cell activa-
tion [40, 41]. These IL-7-induced signals are important for
expression of the glucose transporter Glut1 in T cells [42]
and, intriguingly, decreased Glut1 and glucose uptake have
been associated with increased PD-1 and Tim-3 expression
and T cell exhaustion [43]. Hence it is feasible that absence
of IL-7 signaling during T cell priming promotes expres-
sion of co-inhibitory receptors, perhaps as a consequence
of defective metabolic regulation.
Conclusions
Efforts to translate pre-clinical studies showing efficacy of
anti-IL-7Rα antibodies for the treatment of type 1 diabetes
have been initiated in the clinic [18]. Our study shows that
a limited treatment with anti-IL-7Rα antibodies is suffi-
cient to induce detectable changes in the peripheral blood
T cell phenotype, increasing expression of several co-
inhibitory receptors in CD4+ and CD8+ TE/M cells and




















































































































































Fig. 6 T cells from anti-IL-7Rα-treated mice are sensitized for TCR-triggered co-inhibitory receptor induction. Female, prediabetic NOD mice (10–11
weeks) were treated with anti-IL-7Rα or rat IgG antibodies twice a week for 2 weeks. At the end of treatment, PLN were harvested and cells stimulated
in vitro with anti-CD3 and anti-CD28 antibodies. a Representative dot plots (left) show percentages of LAG-3- and Foxp3-expressing cells within the
CD4+ T cell gate 72 h after stimulation; summary (right) of LAG-3 expression levels (MFI) in the indicated cell populations stimulated with 0.1 μg/ml
(white circles) or 10 μg/ml (black diamonds) anti-CD3. b Representative dot plots (left) and summary graph (right) show percentages of Tim-3+ CD44high
cells within the CD8+ T population, stimulated as indicated. Each symbol represents an individual mouse (n = 3–6). Data are representative for two
independent experiments. * = p≤ 0.05
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rationale for clinical trials with anti-IL-7Rα mAbs and
suggest that a T cell biomarker in the blood based on co-
inhibitory receptor expression may be helpful in following
individual patients’ response to IL-7Rα blockade. The
shorter, 3-week course of treatment we tested here lost
some efficacy to prevent type 1 diabetes compared to per-
sistent treatment [4], suggesting that it may be ideally
suited to combine with another intervention to improve
efficacy while maintaining the increased safety profile pre-
sumably associated with limited treatment duration.
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